



May 10, 2024

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Outcome of Board Meeting held on May 10, 2024

Ref: Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. May 10, 2024 inter-alia approved the following(s):

Financial Results

1. Considered and approved the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial Year ended March 31, 2024.

A signed copy of the above Financial Results (Standalone & Consolidated) along with Auditors' Reports thereon is attached herewith as “**Annexure – A**” and a declaration under Regulation 33 of the Listing Regulations, signed by Group Chief Financial Officer in respect of Audit Reports issued by Statutory Auditors with unmodified opinion is attached herewith as “**Annexure- B**”.

Final Dividend

2. Recommendation of final dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the financial year ended March 31, 2024 subject to approval of the Shareholders at ensuing Annual General Meeting (“AGM”) of the Company. The record date for the purpose of payment of final dividend shall be June 10, 2024.

Annual General Meeting

3. Convening of 30th Annual General Meeting (AGM) of the Company on Saturday, June 29, 2024, through Video Conferencing/ Other Audio-Visual Means (VC/OVAM).

ESOP

4. Allotment of 2,500 Equity Shares under Employee Stock Option Plan 2010 (“ESOP 2010 Plan”) of the Company.

Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company increased to INR 83,48,03,520/- divided into 8,34,80,352 Equity Shares of INR 10/- each.



5. Grant of ESOPs to eligible employees under Company's RSU Plan 2016.

The disclosure with respect to the grant of ESOPs, as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as **Annexure - C**.

Re- Appointment(s)

6. Re-appointment of Dr. Vandana Lal (DIN: 00472955) as Whole-Time Director of the Company, for a period of Five (5) years commencing from April 01, 2025, subject to approval of Shareholders of the Company at the ensuing AGM.

Further, please take note that Dr. Vandana Lal is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority.

7. Re-appointment of M/s Ernst & Young LLP (EY) as the Internal Auditors of the Company for the Financial Year 2024-25.
8. Re-appointment of M/s A.G. Agarwal & Associates as the Cost Auditors of the Company for the Financial Year 2024-25.

The disclosure with respect to the above re-appointment(s), as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as **Annexure - D**.

The Board Meeting commenced at 11:15 A.M. (IST) and concluded at 1:35 P.M (IST)

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
Dr. Lal PathLabs Limited**

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended 31 March, 2024 and (b) reviewed the Consolidated Financial Results for the quarter ended 31 March, 2024 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended 31 March, 2024" of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), ("the Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of subsidiaries referred to in Other Matters section below, the Consolidated Financial Results for the year ended 31 March, 2024:

- (i) includes the results of the following entities:
 - a) Parent Company
Dr Lal PathLabs Limited
 - b) Subsidiaries held directly
 1. Paliwal Diagnostics Private Limited
 2. Paliwal Medicare Private Limited
 3. Dr. Lal PathLabs Nepal Private Limited
 4. Dr. Lal PathLabs Bangladesh Private Limited
 5. Dr. Lal Ventures Private Limited
 6. PathLabs Unifiers Private Limited
 7. Dr. Lal PathLabs Kenya Private Limited
 8. Suburban Diagnostics (India) Private Limited
 - c) Subsidiaries held indirectly
 1. Centrapath Labs Private Limited
 2. APRL PathLabs Private Limited
 3. Chanre Laboratory Private Limited
- (ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the year ended 31 March, 2024.



(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended 31 March, 2024

With respect to the Consolidated Financial Results for the quarter ended 31 March, 2024, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended 31 March, 2024, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended 31 March, 2024

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended 31 March, 2024 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended 31 March, 2024, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended 31 March, 2024 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Dh

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended 31 March, 2024

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended 31 March, 2024 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.



Deloitte Haskins & Sells LLP

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended 31 March, 2024

We conducted our review of the Consolidated Financial Results for the quarter ended 31 March, 2024 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- The Statement includes the results for the quarter ended 31 March, 2024 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit the financial statements/ financial information of three subsidiaries included in the consolidated financial results, whose financial statements / financial information reflect total assets of INR 224 million as at 31 March, 2024 and total revenues of INR 45 million and INR 169 million for the quarter and year ended 31 March, 2024 respectively, total net profit/(loss) after tax of INR (1) million and INR Nil million for the quarter and year ended 31 March, 2024 respectively and total comprehensive income/(loss) of INR 1 million and INR (1) million for the quarter and year ended 31 March, 2024 respectively and net cash outflows of INR 34 million for the year ended 31 March, 2024, as considered in the Statement. These financial statements/financial information have been audited/ reviewed, as applicable, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.


Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Jitendra Agarwal
Partner

(Membership No. 87104)
(UDIN: 24087104BKCUDK7772)

Place: New Delhi
Date: 10 May, 2024



Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited/Audited Financial Results for the quarter and year ended ended 31 March, 2024

(in INR million except as stated)

Particulars	3 months ended 31 March, 2024	Preceding 3 months ended 31 December, 2023	Corresponding 3 months ended in previous year 31 March, 2023	Year ended 31 March, 2024	Previous year ended 31 March, 2023
	(see note iv)		(see note iv)	(see note iv)	(see note iv)
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1 Income					
(a) Revenue from operations	5,454	5,389	4,910	22,266	20,169
(b) Other income	184	183	142	692	417
Total income	5,638	5,572	5,052	22,958	20,586
2 Expenses					
(a) Cost of materials consumed	1,089	1,070	1,059	4,514	4,472
(b) Employee benefits expense	1,054	1,090	925	4,245	3,765
(c) Finance costs	66	70	90	294	375
(d) Depreciation and amortisation expense	366	360	376	1,436	1,502
(e) Fees to collection centers/channel partners	756	777	688	3,130	2,820
(f) Other expenses	1,108	1,046	1,082	4,284	4,213
Total expenses	4,439	4,413	4,220	17,903	17,147
3 Profit before tax	1,199	1,159	832	5,055	3,439
4 Tax expense					
(a) Current tax	326	344	230	1,480	1,079
(b) Deferred tax	15	(7)	33	(48)	(51)
Total tax expense	341	337	263	1,432	1,028
5 Profit for the period (A)	858	822	569	3,623	2,411
6 Other comprehensive income/(loss)					
Items that will not be reclassified to profit or loss					
-Remeasurement of the defined benefit obligations	(13)	4	(24)	(5)	26
-Income tax in relation to the items that will not be reclassified to profit or loss	3	(1)	6	1	(6)
Items that may be reclassified to profit or loss					
-Exchange differences on translation of foreign operations	1	(1)	(2)	(2)	(4)
Total other comprehensive income/(loss) (B)	(9)	2	(20)	(6)	16
7 Total comprehensive income (A+B)	849	824	549	3,617	2,427
Profit for the period attributable to:					
-Owners of the Company	845	813	567	3,577	2,389
-Non-controlling interests	13	9	2	46	22
	858	822	569	3,623	2,411
Other comprehensive income/(loss) for the period attributable to:					
-Owners of the Company	(9)	2	(20)	(6)	16
-Non-controlling interests	-	-	-	-	-
	(9)	2	(20)	(6)	16
Total comprehensive income for the period attributable to:					
-Owners of the Company	837	815	547	3,572	2,405
-Non-controlling interests	12	9	2	45	22
	849	824	549	3,617	2,427
8 Paid-up equity share capital (Face Value of INR 10 per share)	835	835	834	835	834
9 Other equity				17,658	15,829
10 Earnings per share (INR) (Face value of INR 10 per share) (not annualised)					
-Basic	10.13	9.77	6.84	43.05	28.82
-Diluted	10.12	9.76	6.82	42.98	28.74


For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 10 May, 2024 respectively. The consolidated financial results for the year ended 31 March, 2024 have been audited and for the quarter ended 31 March, 2024 have been reviewed by the statutory auditors of the Company and they have issued an unmodified report thereon.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as the Group).
- iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India.
- iv. Figures for the quarter ended 31 March, 2024 and 31 March, 2023 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2023 and 31 December, 2022 respectively, which was subjected to limited review.
- v. During the year ended 31 March 2024, the Parent Company has issued 60,000 equity shares of face value of INR 10 each, on exercise of employee stock options.
Further, during the year ended 31 March 2024, the Parent Company has issued 49,975 equity shares of face value of INR 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
Subsequent to the year end 31 March 2024, the Parent Company has issued 2,500 equity shares of face value of INR 10 each on exercise of employee stock options.
- vi. The Board of Directors of the Parent Company had approved first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 27 July, 2023 and this was paid on 23 August, 2023. The Board of Directors of the Parent Company had approved second interim dividend of INR 12 per equity share (face value of INR 10 each) at their meeting held on 1 February, 2023 and this was paid on 23 February, 2024.
The Board of Directors of the Parent Company at their meeting held on 10 May 2024 has proposed final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2024. The total dividend for the year including the final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) is INR 24 per equity share having face value of INR 10 each.
The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2023. The same was approved by the shareholders in the Annual General Meeting held on 12 September, 2023 and this was paid on 15 September, 2023.
- vii. The Board of Directors of the subsidiaries, Paliwal Medicare Private Limited (PMPL) and Paliwal Diagnostics Private Limited (PDPL) in their meetings held on 25 October, 2021 and 25 October, 2021 respectively had approved the "Scheme of Amalgamation" of PMPL with PDPL w.e.f 1 April, 2021, the appointed date. As per the said scheme, the undertaking of PMPL shall stand transferred to and vested in PDPL on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by National Company Law Tribunal and other statutory approvals.
- viii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- ix. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'ble) Brig. Dr. Arvind Lal
Executive Chairman

Place: New Delhi
Date: 10 May, 2024

For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited		
Statement of Consolidated Assets and Liabilities		
(in INR million except as stated)		
Particulars	As at 31 March, 2024	As at 31 March, 2023
	(Audited)	(Audited)
Assets		
1 Non-current assets		
(a) Property, plant and equipment	1,994	2,004
(b) Right-of-use assets	1,436	2,006
(c) Capital work-in-progress	40	30
(d) Investment property	337	-
(e) Goodwill	5,482	5,478
(f) Other intangible assets	3,026	3,562
(g) Intangible assets under development	17	20
(h) Financial assets		
(i) Loans	-	1
(ii) Other financial assets	317	401
(i) Non-current tax assets (net)	174	205
(j) Deferred tax assets (net)	449	404
(k) Other non-current assets	21	14
Total non-current assets	13,293	14,125
2. Current assets		
(a) Inventories	373	338
(b) Financial assets		
(i) Investments	1,138	1,499
(ii) Trade receivables	774	708
(iii) Cash and cash equivalents	3,609	2,637
(iv) Bank balances other than (iii) above	4,694	4,017
(v) Loans	13	14
(vi) Other financial assets	470	357
(c) Other current assets	196	160
Total current assets	11,267	9,730
Total assets	24,560	23,855
Equity and liabilities		
1. Equity		
(a) Equity share capital	835	834
(b) Other equity	17,658	15,829
Equity attributable to the owners of the Company	18,493	16,663
Non-controlling interests	361	332
Total equity	18,854	16,995
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	833
(ii) Lease liabilities	1,030	1,300
(b) Deferred tax liabilities (net)	24	29
Total non-current liabilities	1,054	2,162
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	833	1,533
(ii) Lease liabilities	606	529
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises;	68	66
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,798	1,495
Sub-total	1,866	1,561
(iv) Other financial liabilities	487	463
(b) Provisions	379	291
(c) Current tax liabilities (net)	133	5
(d) Other current liabilities	348	316
Total current liabilities	4,652	4,698
Total liabilities	5,706	6,860
Total equity and liabilities	24,560	23,855

Dr. Lal PathLabs Limited
Consolidated Cash Flow Statement

(in INR million except as stated)

Particulars	Year ended 31 March, 2024	Year ended 31 March, 2023
	(Audited)	(Audited)
Cash flows from operating activities		
Profit for the year	3,623	2,411
Adjustments for :		
Tax expense	1,432	1,028
Interest income	(554)	(332)
Gain on sale or fair valuation of investments (at FVTPL)	(104)	(64)
Surrender value of keyman insurance policy (at FVTPL)	(9)	(7)
Rental income from investment property	(20)	-
Sundry balances written back	-	(5)
(Profit)/Loss on disposal/discard of property, plant and equipment	2	(8)
Expense recognised in respect of employee share based compensation	217	228
Finance costs	294	375
Depreciation and amortisation expense	1,436	1,502
Provision for impairment of trade receivables and advances	-	76
Provision for impairment of trade receivables and advances written back	(3)	-
Bad debts / advances written off (net)	10	36
Security deposits amortisation	-	8
Remeasurement of the defined benefit obligation	(5)	26
Exchange differences on translation of foreign operations	(2)	(4)
Operating profit before working capital changes	6,317	5,270
Changes in working capital:		
Adjustment for (increase)/decrease in operating assets:		
(Increase)/decrease in inventories	(35)	187
(Increase)/decrease in trade receivables	(73)	33
(Increase)/decrease in loans	1	(2)
(Increase)/decrease in other financial assets	17	11
(Increase)/decrease in other assets	(39)	22
Adjustment for increase/(decrease) in operating liabilities:		
Increase/(decrease) in trade payables	305	92
Increase/(decrease) in other financial liabilities	61	21
Increase/(decrease) in provisions	87	21
Increase/(decrease) in other liabilities	33	(30)
Cash generated from operations	6,674	5,625
Income taxes paid (Net)	(1,320)	(1,065)
Net cash generated from operating activities (a)	5,354	4,560
Cash flows from investing activities		
Payments for purchase of property, plant and equipment	(512)	(365)
Proceeds from disposal of property, plant and equipment	9	5
Payments for purchase of other intangible assets	(63)	(81)
Rental income from investment property	20	-
Interest received	453	306
Payments for business purchase on slump sale basis*	-	(14)
Net cash outflow for investment in subsidiaries	(4)	(164)
Payments for purchase of investments in mutual funds	(3,420)	(3,498)
Proceeds from sale of investments in mutual funds	3,886	2,717
Bank deposits placed with the banks	(6,397)	(7,849)
Bank deposits with banks encashed	5,785	6,070
Net cash used in investing activities (b)	(243)	(2,873)
Cash flows from financing activities		
Proceeds from exercise of share options	35	9
Repayment of application money received at the time of IPO	-	(1)
Repayment of borrowings	(1,533)	(1,090)
Interest paid	(94)	(155)
Repayment of lease liability	(335)	(342)
Interest paid on lease liability	(200)	(223)
Dividend paid on equity shares	(2,012)	(1,030)
Net cash used in financing activities (c)	(4,139)	(2,832)
Net increase in cash and cash equivalents (a+b+c)	972	(1,145)
Cash and cash equivalents at the beginning of the year	2,637	3,782
Cash and cash equivalents at the end of the year	3,609	2,637
Components of cash and cash equivalents		
Cash on hand	18	12
Balance with scheduled banks:		
- on current accounts	210	118
- on cash credit accounts	20	5
- deposits with maturity of less than 3 months	3,361	2,502
Cash and cash equivalents in Cash Flow Statement	3,609	2,637

For Identification Only
Deloitte Haskins & Sells LLP

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
Dr. Lal PathLabs Limited

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended 31 March, 2024 and (b) reviewed the Standalone Financial Results for the quarter ended 31 March, 2024 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended 31 March, 2024" of **Dr. Lal PathLabs Limited** ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended 31 March, 2024:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended 31 March, 2024

With respect to the Standalone Financial Results for the quarter ended 31 March, 2024, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended 31 March, 2024, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended 31 March, 2024

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended 31 March, 2024 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



Management's Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended 31 March, 2024 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended 31 March, 2024 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended 31 March, 2024

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended 31 March, 2024 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



Deloitte Haskins & Sells LLP

- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended 31 March, 2024

We conducted our review of the Standalone Financial Results for the quarter ended 31 March, 2024 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- The Statement includes the results for the Quarter ended 31 March, 2024 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our report on the Statement is not modified in respect of this matter.


For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal
Partner

(Membership No. 87104)
(UDIN: 24087104BKCUDJ8088)

Place: New Delhi
Date: 10 May, 2024



Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Standalone Unaudited/Audited Financial Results for the quarter and year ended 31 March, 2024

(in INR million except as stated)

Particulars	3 months ended 31 March, 2024	Preceding 3 months ended 31 December, 2023	Corresponding 3 months ended in previous year 31 March, 2023	Year ended 31 March, 2024	Previous year ended 31 March, 2023
	(See note iii)	(See note iii)	(See note iii)	(See note iii)	(See note iii)
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1 Income					
(a) Revenue from operations	4,790	4,760	4,310	19,668	17,690
(b) Other income	159	151	116	601	466
Total income	4,949	4,911	4,426	20,269	18,156
2 Expenses					
(a) Cost of materials consumed	948	927	903	3,908	3,896
(b) Employee benefits expense	903	934	769	3,636	3,155
(c) Finance costs	59	65	84	268	344
(d) Depreciation and amortisation expense	198	192	208	765	821
(e) Fees to collection centers/channel partners	707	727	648	2,948	2,665
(f) Other expenses	929	871	833	3,584	3,367
Total expenses	3,744	3,716	3,445	15,109	14,248
3 Profit before tax	1,205	1,195	981	5,160	3,908
4 Tax expense					
(a) Current tax	300	319	221	1,376	1,014
(b) Deferred tax	10	(7)	46	(60)	(30)
Total tax expense	310	312	267	1,316	984
5 Profit for the period (A)	895	883	714	3,844	2,924
6 Other comprehensive income/(loss)					
Items that will not be reclassified to profit or loss					
-Remeasurement of the defined benefit obligations	(6)	1	(21)	(4)	26
-Income tax in relation to the items that will not be reclassified to profit or loss	2	(1)	5	1	(7)
Total other comprehensive income/(loss) (B)	(4)	-	(16)	(3)	19
7 Total comprehensive income (A+B)	891	883	698	3,841	2,943
8 Paid-up equity share capital (Face Value of INR 10 per share)		835	834	835	834
9 Other equity				18,162	16,065
10 Earnings per share (INR) (Face value of INR 10 per share) (not annualised)					
- Basic	10.73	10.78	8.61	46.25	35.28
- Diluted	10.71	10.75	8.58	46.18	35.17


For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 10 May, 2024. The financial results for the year ended 31 March, 2024 have been audited and for the quarter ended 31 March, 2024 have been reviewed by the statutory auditors of the Company and they have issued an unmodified report thereon.
- ii. These financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India.
- iii. Figures for the quarter ended 31 March, 2024 and 31 March, 2023 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2023 and 31 December, 2022 respectively, which was subjected to limited review.
- iv. During the year ended 31 March 2024, the Company has issued 60,000 equity shares of face value of INR 10 each, on exercise of employee stock options.
Further, during the year ended 31 March 2024, the Company has issued 49,975 equity shares of face value of INR 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
Subsequent to the year end, the Company has issued 2,500 equity shares of face value of INR 10 each on exercise of employee stock options.
- v. The Board of Directors of the Company had approved first interim dividend of INR. 6 per equity share (face value of INR 10 each) at their meeting held on 27 July, 2023 and this was paid on 23 August, 2023. The Board of Directors of the Company had approved second interim dividend of INR 12 per equity share (face value of INR 10 each) at their meeting held on 1 February, 2024 and this was paid on 23 February, 2024.
The Board of Directors of the Company at their meeting held on 10 May 2024 has proposed final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) of Rs. INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2024. The total dividend for the year including the final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) is INR 24 per equity share having face value of INR 10 each.
The Board of Directors of the Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2023. The same was approved by the shareholders in the Annual General Meeting held on 12 September, 2023 and this was paid on 15 September, 2023.
- vi. During the year ended 31 March, 2024 the Company has made further investment of INR 8 million in its wholly owned subsidiary, Suburban Diagnostics (India) Private Limited (SDIPL) through purchase of ESOPs.
- vii. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- viii. Refer Annexure A for Statement of Standalone Assets and Liabilities.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'y) Brig. Dr. Arvind Lal
Executive Chairman

Place: New Delhi
Date: 10 May, 2024

For Identification Only
Deloitte Haskins & Sells LLP

Annexure A


Dr. Lal PathLabs Limited Statement of Standalone Assets and Liabilities (in INR million except as stated)		
Particulars	As at 31 March, 2024	As at 31 March, 2023
	(Audited)	(Audited)
Assets		
1. Non-current assets		
(a) Property, plant and equipment	1,666	1,661
(b) Right-of-use assets	1,274	1,791
(c) Capital work-in-progress	40	30
(d) Investment property	337	-
(e) Goodwill	11	11
(f) Other intangible assets	139	152
(g) Intangible assets under development	17	20
(h) Financial assets		
(i) Investments	10,728	10,720
(ii) Loans	-	1
(iii) Other financial assets	199	249
(i) Non-current tax assets (net)	135	130
(j) Deferred tax assets (net)	386	326
(k) Other non-current assets	17	10
Total non-current assets	14,949	15,101
2. Current assets		
(a) Inventories	275	233
(b) Financial assets		
(i) Investments	700	1,414
(ii) Trade receivables	778	633
(iii) Cash and cash equivalents	3,258	2,203
(iv) Bank balances other than (iii) above	3,573	3,139
(v) Loans	12	12
(vi) Other financial assets	418	314
(c) Other current assets	191	153
Total current assets	9,205	8,101
Total assets	24,154	23,202
Equity and Liabilities		
1. Equity		
(a) Equity share capital	835	834
(b) Other equity	18,162	16,065
Total equity	18,997	16,899
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	833
(ii) Lease liabilities	913	1,148
Total non-current liabilities	913	1,981
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	833	1,533
(ii) Lease liabilities	528	440
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises;	60	61
Total outstanding dues of creditors other than micro enterprises and small enterprises;	1,613	1,341
Subtotal	1,673	1,402
(iv) Other financial liabilities	455	429
(b) Provisions	306	232
(c) Current tax liabilities (net)	132	5
(d) Other current liabilities	317	281
Total current liabilities	4,244	4,322
Total liabilities	5,157	6,303
Total equity and liabilities	24,154	23,202

For Identification Only
Deloitte Haskins & Sells LLP

Annexure B

Dr. Lal PathLabs Limited Standalone Cash Flow Statement		
(in INR million except as stated)		
Particulars	Year ended 31 March, 2024	Year ended 31 March, 2023
	(Audited)	(Audited)
Cash flows from operating activities		
Profit for the year	3,844	2,924
Adjustments for :		
Tax expense	1,316	984
Interest income	(447)	(275)
Dividend income from a subsidiary company	(32)	(120)
Gain on sale or fair valuation of investments (at FVTPL)	(88)	(48)
Surrender value of keyman insurance policy (at FVTPL)	(9)	(7)
Rental income from investment property	(20)	-
(Profit)/Loss on disposal/discard of property, plant and equipment	(3)	(15)
Expense recognised in respect of employee share based compensation	208	213
Finance costs	268	344
Depreciation and amortisation expense	765	821
Provision for impairment of trade receivables and advances	1	15
Bad debts / advances written off (net)	3	2
Security deposits amortisation	-	8
Remeasurement of the defined benefit obligation	(4)	26
Operating profit before working capital changes	5,802	4,872
Changes in working capital:		
Adjustment for (increase)/decrease in operating assets:		
(Increase)/decrease in Inventories	(42)	165
(Increase)/decrease in trade receivables	(149)	20
(Increase)/decrease in loans	1	(3)
(Increase)/decrease in other financial assets	11	7
(Increase)/decrease in other assets	(32)	7
Adjustment for increase/(decrease) in operating liabilities:		
Increase/(decrease) in trade payables	272	167
Increase/(decrease) in other financial liabilities	57	15
Increase/(decrease) in provisions	74	26
Increase/(decrease) in other liabilities	36	(9)
Cash generated from operations	6,030	5,267
Income taxes paid (net)	(1,254)	(991)
Net cash generated from operating activities (a)	4,776	4,276
Cash flows from investing activities		
Payments for purchase of property, plant and equipment	(449)	(317)
Proceeds from disposal of property, plant and equipment	8	1
Payments for purchase of other intangible assets	(44)	(63)
Dividend received from a subsidiary company	32	120
Rental income from investment property	20	-
Interest received	357	274
Net cash outflow for investment in subsidiaries	(8)	(220)
Payments for purchase of investments in mutual funds	(2,843)	(3,076)
Proceeds from sale of investments in mutual funds	3,645	1,710
Bank deposits placed with the banks	(5,714)	(6,765)
Bank deposits with banks encashed	5,314	5,450
Net cash flow from/(used in) investing activities (b)	318	(2,886)
Cash flows from financing activities		
Proceeds from exercise of share options	35	9
Repayment of application money received at the time of IPO	-	1
Repayment of borrowings	(1,533)	(1,088)
Interest paid	(93)	(151)
Repayment of lease liability	(278)	(285)
Interest paid on lease liability	(175)	(192)
Dividend paid on equity shares	(1,995)	(994)
Net cash used in financing activities (c)	(4,039)	(2,700)
Net increase in cash and cash equivalents (a+b+c)	1,055	(1,310)
Cash and cash equivalents at the beginning of the year	2,203	3,513
Cash and cash equivalents at the end of the year	3,258	2,203
Components of cash and cash equivalents		
Cash on hand	14	8
Balance with scheduled banks:		
- on current accounts	124	44
- on cash credit accounts	20	5
- deposits with maturity of less than 3 months	3,100	2,146
Cash and cash equivalents in Cash Flow Statement	3,258	2,203

For Identification Only
Deloitte Haskins & Sells LLP



May 10, 2024

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015, we hereby confirm that the Audit Report issued by M/s Deloitte Haskins & Sells LLP, Statutory Auditors of the Company on the Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended March 31, 2024 is with Unmodified Opinion.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Ved Prakash Goel
Group Chief Financial Officer



Disclosure as per Regulation 30 of Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 dated July 13, 2023:

Sl. No.	Particulars	Details of RSU Plan 2016
a)	Brief details of Options granted	18,000 (Eighteen Thousand) Options have been granted on May 10, 2024
b)	Whether the scheme is in terms of SEBI (Share Based Employee Benefit and Sweat Equity) Regulations, 2021	Yes
c)	Total number of shares covered by these Options	18,000 (Eighteen Thousand) equity shares of face value of Rs. 10/- each fully paid-up
d)	Pricing formula	Exercise price of Rs. 10/- per option
e)	Options vested	Not applicable
f)	Time within which Option may be exercised	5 years from the date of vesting
g)	Options exercised	Not applicable
h)	Money realized by exercise of Options	Not applicable
i)	The total number of shares arising as a result of exercise of Option	Not applicable
j)	Options lapsed	Not applicable
k)	Variation of terms of Options	There is no variation
l)	Brief details of significant terms	The Options granted under RSU Plan 2016 would Vest not before one (01) year and not later than four (04) years from the date of grant of such Options. The Options not exercised within the Exercise Period shall lapse.
m)	Subsequent changes or cancellation or exercise of such Options	There is no change or cancellation, or exercise.
n)	Diluted earnings per share pursuant to issue of equity shares on exercise of Options	Options are yet to be exercised

Disclosure as per Regulation 30 of Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 dated July 13, 2023:

Sl. No.	Particulars	Details		
		M/s Ernst & Young LLP (EY) (Internal Auditors)	M/s A.G. Agarwal & Associates (Cost Auditors)	Dr. Vandana Lal (Whole Time Director)
1	Reasons for change viz appointment/ re-appointment, resignation, removal, death or otherwise	Re-appointment		
2	Date of Appointment/ Re-appointment & term of appointment/ re-appointment	Re-appointed on May 10, 2024 for Financial Year 2024-25		Re-appointed on May 10, 2024, for a period of five (5) years commencing from April 01, 2025, subject to the approval of Shareholders of the Company
3	Brief Profile (in case of appointment)	EY is a global leader in assurance, consulting, strategy and transactions, and tax services. EY exists to build a better working world, helping to create long-term value for clients, people and society, and to build trust in the capital markets. Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.	M/s A.G. Agarwal & Associates have extensive experience in the fields of Cost Accounting, Cost Management, Inventory Audit, Vat Audit, Excise Audit, Valuation, Internal Audit, Fraud Detection, Insurance & Loss Surveyors, Techno Economic Feasibility, Store Audit, Taxation, Auditing, Investigation and Business and Financial consultation.	Dr. Vandana Lal, aged about 68 Years, is the Executive Director of India's largest diagnostics chain and became part of the organization in 1983. She is a distinguished alumnus of Lady Hardinge Medical College, University of Delhi and holds an MD in Pathology. Dr. Vandana Lal has played a pivotal role in revolutionizing the landscape of diagnostic services in India. Her remarkable contributions include the introduction of a diverse range of tests and cutting-edge technologies for the first time in India, as a result of which, today Dr. Lal PathLabs offers close to 5,000 tests & panels. Dr. Vandana Lal is trained in Quality Assurance and spearheads the quality



				<p>implementation process in all the laboratories of Dr. Lal PathLabs. She is renowned for her pioneering efforts in establishing quality accreditations in the field of diagnostics in India, with a record number of 36 labs accredited by National Accreditation Board for Testing and Calibration Laboratories (NABL) and an additional 2 labs accredited by the College of American Pathologists (CAP), USA. She is an International fellow of the College of American Pathologists (IFCAP). During the critical period of the COVID-19 pandemic, Dr. Vandana Lal demonstrated exceptional leadership as the Chair of the NABL Technical Committee for expediting the accreditation process for thousands of laboratories for COVID RTPCR testing.</p> <p>She is also the Chief Technical Officer at Dr. Lal PathLabs and plays a pivotal role in Clinical Research Services and R&D. She has been instrumental in the establishment of the National Reference Lab in Delhi and three regional reference labs in Kolkata, Bengaluru and Mumbai.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	None		Spouse of (Hony) Brig. Dr. Arvind Lal, Executive Chairman and Mother of Dr. Archana Lal Erdmann, Non-Executive Director of the Company